The purpose of this study is to gather information about the long term health of people who have been prescribed the Cologuard test, which is used for colorectal cancer (CRC) screening.
Participates will be consented for prospective follow-up for health outcomes, which will be ascertained through periodic contacts. Participants will complete a baseline health questionnaire survey (T0) and a 1-year follow-up questionnaire survey (T1), allow access to medical records, when available, and allow future contacts for additional surveys.
Study Type
OBSERVATIONAL
Enrollment
150,000
multi-target stool Deoxyribonucleic Acid (MT-sDNA) screening test
Mayo Clinic
Rochester, Minnesota, United States
Enrollment of Subjects
Enrollment of 150,000 subjects
Time frame: 3 years
Diagnostic colonoscopy
Proportion having diagnostic colonoscopy within 1 year after positive CG test
Time frame: 4.5 years
CRC Frequency
Frequency of CRC among enrollees
Time frame: 10 years
National Rates Comparison
Comparison with national rates (i.e., SEER cancer registry rates) adjusted to reflect a) the age- and sex- distribution of CG users, b) that 25% of colorectal cancers occur in high risk patients, and c) the attrition rate of our longitudinal cohort
Time frame: 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.